Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 114 publications
Is Hypercortisolism Treatable? Which Patients Should Be Treated and How-A Practical Guide for Clinicians.
Journal: Diabetes, obesity & metabolism
Published: May 20, 2026
Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity.
Journal: Molecular metabolism
Published: August 12, 2025
Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis.
Journal: Reviews in endocrine & metabolic disorders
Published: August 12, 2025
Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction-Associated Steatohepatitis.
Journal: Alimentary pharmacology & therapeutics
Published: June 19, 2025
Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial.
Journal: Diabetes, obesity & metabolism
Published: May 29, 2025
What is the 'real-world' experience with fixed-ratio combination therapy (insulin + GLP-1 receptor agonist) in routine clinical practice? Take-home messages for clinicians regarding key outcomes.
Journal: Diabetes, obesity & metabolism
Published: May 14, 2025
Safety and Functionality of a Novel Clinical Decision-Support Algorithm with Insulin Efsitora Alfa in Adults with Type 2 Diabetes: Early Feasibility Study.
Journal: Diabetes technology & therapeutics
Published: May 12, 2025
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Journal: Lancet (London, England)
Published: March 24, 2025
Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes.
Journal: Diabetes, obesity & metabolism
Published: November 26, 2024
Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes.
Journal: Diabetes, obesity & metabolism
Published: October 14, 2024
The role of incretin receptor agonists in the treatment of obesity.
Journal: Diabetes, obesity & metabolism
Published: May 03, 2024
Last Updated: 09/26/2026